Attributes | Values |
---|
rdf:type
| |
description
| - wetenschappelijk artikel (nl)
- article scientifique publié en 2015 (fr)
- наукова стаття, опублікована в серпні 2015 (uk)
- im August 2015 veröffentlichter wissenschaftlicher Artikel (de)
- scientific article published on 12 August 2015 (en)
- 2015 թվականի օգոստոսի 12-ին հրատարակված գիտական հոդված (hy)
- artículu científicu espublizáu n'agostu de 2015 (ast)
|
publication date
| |
publication date
| |
exact match
| |
exact match
| |
cites work
| |
cites work
| - Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery
- Antiemetic guidelines: creating a more practical treatment approach
- On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993.
- Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting
- Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study
- Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron
- Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions
- Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis
- Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting.
- Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron
- Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology
- A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy
- Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study
- Abdominal vagal afferent neurones: an important target for the treatment of gastrointestinal dysfunction
- Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Instit
- Serotonin receptor physiology: relation to emesis
- Vagal afferent fibers and peripheral 5-HT3 receptors mediate cisplatin-induced emesis in dogs
- Anti-emetics for cancer chemotherapy-induced emesis: Potential of alternative delivery systems
- Monitoring and evaluation of side effects of chemotherapy in patients with colon cancer
|
author name string
| |
author name string
| - Hyo Jeong Kim
- Young Jin Choi
- Sung Yong Oh
- Yang Soo Kim
- Eun Mi Lee
- Won Sik Lee
- Joo Seop Chung
- Eun Young Yun
- Su Jin Koh
- Young Mi Seol
- Young Don Joo
- Jin Ho Baek
- Hyun Gi Lee
|
rdfs:label
| - Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study (en)
- Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study (nl)
|
skos:prefLabel
| - Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study (en)
- Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study (nl)
|
name
| - Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study (en)
- Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study (nl)
|
title
| |
title
| - Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study (en)
|
page(s)
| |
page(s)
| |
instance of
| |
instance of
| |
main subject
| |
main subject
| |
PubMed ID
| |
PubMed ID
| |
PubMed ID
| |
published in
| |
published in
| |
issue
| |